Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: LPCN
- Previous Close: $3.91
- 50 Day Moving Average: $3.62
- 200 Day Moving Average: $3.71
- 52-Week Range: $2.51 - $12.66
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.12
- P/E Growth: 0.00
- Market Cap: $71.40M
- Outstanding Shares: 18,260,000
- Beta: 1.88
- Return on Equity: -59.35%
- Return on Assets: -55.10%
Companies Related to Lipocine:
- Current Ratio: 18.73%
- Quick Ratio: 18.73%
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?
3 analysts have issued twelve-month target prices for Lipocine's shares. Their predictions range from $15.00 to $30.00. On average, they expect Lipocine's share price to reach $23.33 in the next year.
When will Lipocine announce their earnings?
Lipocine is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns Lipocine stock?
Lipocine's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Royce & Associates LP (6.46%), Dimensional Fund Advisors LP (1.42%), State Street Corp (1.29%) and Federated Investors Inc. PA (0.45%). Company insiders that own Lipocine stock include John W Higuchi and Mahesh V Patel.
Who sold Lipocine stock? Who is selling Lipocine stock?
Lipocine's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP.
Who bought Lipocine stock? Who is buying Lipocine stock?
Lipocine's stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, State Street Corp and Federated Investors Inc. PA. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi and Mahesh V Patel.
How do I buy Lipocine stock?
Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Lipocine stock cost?
One share of Lipocine stock can currently be purchased for approximately $3.91.